Editor's note

This article was originally published in December 2015 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

A landmark approval, with caveats

Mexico's COFEPRIS granted regulatory approval to Sanofi-Pasteur's Dengvaxia (CYD-TDV) on 9 December 2015 - making it the world's first licensed dengue vaccine after more than two decades of development. The approval followed Phase III clinical trials conducted across Asia and Latin America involving over 30,000 participants, which had demonstrated overall vaccine efficacy of approximately 60-65% against symptomatic dengue and notably higher efficacy (~93%) against severe dengue hospitalisation. However, the aggregate efficacy figure masked important serotype-specific variation and, critically, variation in efficacy depending on the subject's prior dengue serostatus.

The serostatus problem

Analysis of the CYD14 and CYD15 Phase III trials had demonstrated a pattern with significant implications: Dengvaxia appeared to protect seropositive individuals effectively (those with prior dengue infection), but in seronegative individuals - particularly children - the vaccine appeared to potentially increase the risk of severe dengue hospitalisation in the years following vaccination. This finding, which would become central to the subsequent Philippine immunisation programme controversy, was not fully apparent at the time of approval but was beginning to emerge in the post-hoc analyses available in late 2015.

Dengvaxia Phase III Efficacy
~65%

Overall Dengvaxia efficacy against symptomatic dengue across the CYD14/15 Phase III trials - with significantly higher efficacy in seropositive subjects and lower in seronegative individuals

"Dengvaxia's approval is a scientific achievement - but the serostatus question is a commercial time bomb that public health programmes will need to navigate very carefully if they are to avoid a serious adverse event crisis."